(Q42168730)

English

Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer

scientific article published on 12 March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 October 2017

Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer (English)

1 reference

Europe PubMed Central

17 October 2017

phase II clinical trial

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

17 October 2017

author name string

Tomaso Prayer-Galetti

1

1 reference

Europe PubMed Central

17 October 2017

Francesco Pagano

3

1 reference

Europe PubMed Central

17 October 2017

Marina Gardiman

4

1 reference

Europe PubMed Central

17 October 2017

Antonio Cisternino

5

1 reference

Europe PubMed Central

17 October 2017

Giovanni Betto

6

1 reference

Europe PubMed Central

17 October 2017

Paola Sperandio

7

1 reference

Europe PubMed Central

17 October 2017

publication date

12 March 2007

1 reference

Europe PubMed Central

17 October 2017

BJU International

1 reference

Europe PubMed Central

17 October 2017

100

1 reference

Europe PubMed Central

17 October 2017

2

1 reference

Europe PubMed Central

17 October 2017

274-280

1 reference

Europe PubMed Central

17 October 2017

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Adjunctive therapy for men with high risk localized and locally advanced prostate cancer: targeting disseminated tumor cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Paclitaxel and docetaxel in prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

High-risk localized prostate cancer: a case for early chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06760.X

21 January 2018

Identifiers

10.1111/J.1464-410X.2007.06760.X

1 reference

Europe PubMed Central

17 October 2017

1 reference

Europe PubMed Central

17 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42168730&oldid=1935124341"